This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of Afatinib or Nintedanib may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for Afatinib and Nintedanib in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
It's about making the connections that count.
Boehringer Ingelheim are always looking for new collaborations and to hear your feedback, please get in touch below.
inOncology.com is a point-of-view–driven medical education website designed to support healthcare professionals (HCPs) in their clinical practice and career. Created by Boehringer Ingelheim, inOncology.com seeks to provide HCPs not only with clinical information but also independent expert opinions to help provide context as well as extensive downloadable resources for continued development.
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Since our foundation in 1885, we have been a family-owned company that believes in evidence-based scientific progress. Working in close collaboration with the international scientific community and some of the world’s leading cancer centres, we have embarked on a major research programme to develop innovative cancer medicines. Our extensive oncology clinical trial programme involves more than 800 study centres in 47 countries and works to ensure that studies with our compounds provide the data that will form a solid basis for your informed decision. We are committed to an €11 billion investment in our 5-year research and development (R&D) programme until 2020, demonstrating a clear commitment to the health of current generations and many to come.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue